Author details

Full Name

Daniel Auclair

Affiliation

ORCID

Career Start Year

1990

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37237081	Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.	Nat Cancer	2023
36702834	Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.	NPJ Genom Med	2023
36631444	Extreme body mass index and survival in newly diagnosed multiple myeloma patients.		2023
36477267	MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.	Cancer Discov	2023
34895486	Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.	Cancer Cell	2022
35653112	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.	Blood Cancer Discov	2022
35945129	High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.	Clin Lymphoma Myeloma Leuk	2022
36969740	Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.	Cancer Res Commun	2022
34148053	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length.	Leukemia	2022
35256844	Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States.	Patient Preference and Adherence	2022
34857028	Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.	Journal of Experimental and Clinical Cancer Research	2021
34321279	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.	Clin Cancer Res	2021
33406420	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.	Cell Rep	2021
31221783	Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma.	Haematologica	2020
32143562	CNV Radar: an improved method for somatic copy number alteration characterization in oncology.	BMC Bioinformatics	2020
32133047	MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21.	Oncotarget	2020
31935283	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.	Blood Adv	2020
32469686	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.	JCO Oncol Pract	2020
32533060	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.	Nat Commun	2020
32616499	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.	Clinical Cancer Research	2020
33392515	Revealing the impact of structural variants in multiple myeloma.	Blood Cancer Discov	2020
29967379	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.	Leukemia	2019
29105742	Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.	British Journal of Haematology	2018
32082000	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.	Leukemia	2018
28642592	Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.	Leukemia	2018
29884741	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.	Blood	2018
29563506	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.	Blood Cancer J	2018
29749396	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.	Leukemia	2018
29166413	Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.	PLoS Genet	2017
28735890	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.	Clin Lymphoma Myeloma Leuk	2017
28428191	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.	Clin Cancer Res	2017
28937974	High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.	Blood Cancer J	2017
25105705	Optimizing dosing of oncology drugs.	Clinical Pharmacology and Therapeutics	2014
24436047	Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.	Cancer Discov	2014
24434212	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.	Cancer Cell	2014
25186949	The genomic landscape of pediatric Ewing sarcoma.	Cancer Discov	2014
24752078	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.	Nat Biotechnol	2014
23334666	The genetic landscape of high-risk neuroblastoma.	Nat Genet	2013
23770567	Mutational heterogeneity in cancer and the search for new cancer-associated genes.	Nature	2013
24185511	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.	Nat Genet	2013
23313954	Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.	Nat Genet	2013
23525077	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.	Nat Genet	2013
23622249	Punctuated evolution of prostate cancer genomes.	Cell	2013
22980975	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.	Cell	2012
22797305	A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.	J Clin Invest	2012
22343534	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	Proc Natl Acad Sci U S A	2012
22622578	Melanoma genome sequencing reveals frequent PREX2 mutations.	Nature	2012
22722202	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012
22820256	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.	Nature	2012
22610119	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.	Nat Genet	2012